Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-31
2011-05-31
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S337000, C514S348000, C514S389000, C514S369000, C514S376000, C514S422000, C548S311400, C548S483000, C548S227000, C548S525000, C546S296000, C546S196000, C546S219000
Reexamination Certificate
active
07951822
ABSTRACT:
The object is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. The solving means is a 1,3-dihydroisobenzofuran derivative represented by the following general formula (1) or salt thereof, or their solvate.
REFERENCES:
patent: 2005/0215577 (2005-09-01), Dehmlow et al.
patent: 199963 (1986-11-01), None
patent: 00/54759 (2000-09-01), None
patent: 02/24632 (2002-03-01), None
patent: 03/082192 (2003-10-01), None
patent: 2004/024161 (2004-03-01), None
patent: 2004/058717 (2004-07-01), None
patent: 2004/072046 (2004-08-01), None
patent: 2005/023188 (2005-03-01), None
Byrn et al. Solid-State Chemistry of Drugs, 2d, Chapter 11 Hydrates and Solvates, 233-247 (1999).
Morissette et al. Adv. Drug Delivery Rev. 2004, 56, 275-300.
Rouhi, Chem. & Eng. News, Feb. 24, 2003, 81(8), 32-35.
Schafer et al. Drug Discovery Today, 13:913 (2008).
Horig et al. Journal of Translational Medicine, 2:44 (2004).
Janowski, Bethany A. et al.; “An oxysterol signalling pathway mediated by the nuclear receptor LXRα”; Nature, vol. 383, Oct. 24, 2006, pp. 728-731.
Lehmann, Jurgen M. et al.; “Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway”; The Journal of Biological Chemistry, vol. 272, No. 6, Feb. 7, 1997, pp. 3137-3140.
Fu, Xuan et al.; “27-Hydroxycholesterol Is an Endogenous Ligand for Liver X Receptor in Cholestrol-loaded Cells”; The Journal of Biological Chemistry, vol. 276, No. 42, Oct. 19, 2001, pp. 38378-38387.
Zelcer, Noam et al.; “Liver X receptors as integrators of metabolic and inflammatory signaling”; The Journal of Clinical Investigation, vol. 116, No. 3, Mar. 2006, pp. 607-614.
Joseph, Sean B. et al.; “Reciprocal regulation of inflammation and lipid metabolism by liver X receptors”: Nature Medicine, vol. 9, No. 2 Feb. 2003, pp. 213-219.
Geyeregger, R. et al.; “Liver X receptors in cardiovascular and metabolic disease”; Cell. Mol. Life Sci., vol. 63, 2006, pp. 524-539.
Peet, Daniel J. et al.; “Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα” Cell, vol. 93, May 29, 1998, pp. 693-704.
Alberti, S. et al.; “Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice”; Journal of Clinical Investigation, Mar. 2001, vol. 107, No. 5, pp. 565-573.
Tangirala, Rajendra K. et al.; “Identification of macrophage liver X receptors as inhibitors of atherosclerosis”; PNAS, vol. 99, No. 18, Sep. 3, 2002, pp. 11896-11901.
Terasaka, Naoki et al.; “T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice” FEBS Letters, vol. 536, 2003, pp. 6-11.
Cao, Guoqing et al.; “Antidiabetic Action of a Liver X Receptor Agonist Mediated by Inhibition of Hepatic Gluconeogenesis”; The Journal of Biological Chemistry, vol. 278, No. 2, Jan. 10, 2003 pp. 1131-1136.
Laffitte, Bryan A. et al.; “Activation of liver X receptor improvers glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue”; PNAS, vol. 100, No. 9, Apr. 29, 2003, pp. 5419-5424.
Lala, Deepak S.; “The Liver X receptors”; Current Opinion in Investigational Drugs, 2005, vol. 6, No. 9, 2005, pp. 934-943.
Groot, Pieter H. E. et al.; “Synthetic LXR agonists increase LDL in CETP species”; Journal of Lipid Research, vol. 46, 2005, pp. 2182-2191.
Schultz, Joshua R. et al.; “Role of LXRs in control of lipogenesis”; Genes & Development, vol. 14, 2000, pp. 2831-2838.
Lu, Timothy T. et al.; “Orphan Nuclear Receptors as eLiXiRs and FiXeRs of Sterol Metabolism”; The Journal of Biological Chemisry, vol. 276, No. 41, Oct. 12, 2001, pp. 37735-37738.
Auboeuf, Didier; “Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator-Activated Receptors and Liver X Receptor α in Humans”; Diabetes, vol. 46, Aug. 1997, pp. 1319-1327.
Lund, Erik G. et al.; “Liver X Receptor Agonists as Potential Therapeutic Agents for Dyslipidemia and Atherosclerosis”; Arterioscler Thromb Vasc Biol., vol. 23, 2003, pp. 1169-1177.
Bradley, Michelle N. et al.; “LXR: A nuclear receptor target for cardiovascular disease?”; Drug Discovery Today: Therapeutic Strategies, 2005, pp. 97-103.
Koura Minoru
Kurobuchi Sayaka
Matsuda Takayuki
Miura Toru
Okuda Ayumu
Barker Michael
Chu Yong
Kowa Company Ltd.
Westerman Hattori Daniels & Adrian LLP
LandOfFree
1,3-dihydroisobenzofuran derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,3-dihydroisobenzofuran derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-dihydroisobenzofuran derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2621294